MARKET

KOD

KOD

Kodiak Sciences Inc.
NASDAQ
26.59
-0.38
-1.41%
Opening 10:17 12/18 EST
OPEN
27.01
PREV CLOSE
26.97
HIGH
27.83
LOW
26.36
VOLUME
102.77K
TURNOVER
--
52 WEEK HIGH
28.79
52 WEEK LOW
1.920
MARKET CAP
1.41B
P/E (TTM)
-6.4556
1D
5D
1M
3M
1Y
5Y
1D
BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks
Reuters · 23h ago
Toro, DBV Technologies, Udemy, ABM Industries And Other Big Stocks Moving Higher On Wednesday
Benzinga · 1d ago
BUZZ-Kodiak Sciences surges after boosted $160 mln equity raise
Reuters · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse
Reuters · 1d ago
BUZZ-Kodiak Sciences dips after boosted $160 mln equity raise
Reuters · 1d ago
Kodiak Sciences 6.956M share Spot Secondary priced at $23.00
TipRanks · 1d ago
Kodiak Sciences prices upsized $160M stock offering at $23.00 per share
Seeking Alpha · 1d ago
*Kodiak Sciences Prices Upsized Underwritten Public Offering of 6.96M Shares at $23.00 Per Share>KOD
Dow Jones · 1d ago
More
About KOD
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Webull offers Kodiak Sciences Inc stock information, including NASDAQ: KOD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KOD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KOD stock methods without spending real money on the virtual paper trading platform.